Revvity to Present at Upcoming Investor Conferences

Rhea-AI Summary

Revvity (NYSE: RVTY) has announced its participation in four major investor conferences during March 2025. The company's leadership team will present at the following events:

- 46th Annual Raymond James Institutional Investor Conference (March 3, 7:30 a.m. ET) featuring CFO Max Krakowiak
- TD Cowen 45th Annual Health Care Conference (March 4, 9:10 a.m. ET) with CEO Prahlad Singh
- Leerink Partners Global Healthcare Conference (March 11, 8:00 a.m. ET) featuring CEO Prahlad Singh
- KeyBanc Capital Markets Healthcare Forum (March 19, 9:00 a.m. ET) with Steve Willoughby, SVP of Investor Relations

The presentations will provide updates on the company's strategic priorities. Live audio webcasts will be available on the company's website, with replays accessible for at least 30 days following the events.

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025:

46^th Annual Raymond James Institutional Investor Conference
Monday, March 3, 2025
7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer

TD Cowen 45^th Annual Health Care Conference
Tuesday, March 4, 2025
9:10 a.m. ET - Prahlad Singh, president and chief executive officer

Leerink Partners Global Healthcare Conference
Tuesday, March 11, 2025
8:00 a.m. ET - Prahlad Singh

KeyBanc Capital Markets Healthcare Forum
Wednesday, March 19, 2025
9:00 a.m. ET - Steve Willoughby, senior vice president, investor relations, ESG, risk

Attendees will receive an update on the Company and its strategic priorities.

Live audio webcasts will be available on the Events section of the Company’s website. Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days.

About Revvity

At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.

With 2024 revenue of more than $2.7 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 160 countries.

Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250220466382/en/

Investor Relations:

Steve Willoughby

steve.willoughby@revvity.com

Media Relations:

Chet Murray

(781) 462-5126

chet.murray@revvity.com

Source: Revvity

FAQ

When is Revvity (RVTY) presenting at the Raymond James Investor Conference in March 2025?

Revvity will present at the Raymond James Institutional Investor Conference on Monday, March 3, 2025, at 7:30 a.m. ET, with CFO Max Krakowiak speaking.

How many investor conferences will Revvity (RVTY) attend in March 2025?

Revvity will attend four investor conferences in March 2025, including Raymond James, TD Cowen, Leerink Partners, and KeyBanc Capital Markets events.

Where can investors access Revvity's (RVTY) March 2025 conference presentations?

Live audio webcasts will be available on the Events section of Revvity's website, with replays accessible on the Investor Relations website for at least 30 days after the events.

Which Revvity (RVTY) executives are presenting at the March 2025 investor conferences?

Presenting executives include CFO Max Krakowiak, CEO Prahlad Singh (at two conferences), and SVP Steve Willoughby.

What topics will be covered in Revvity's (RVTY) March 2025 investor conference presentations?

The presentations will provide updates on the company and its strategic priorities.